Head and Neck Specialists

Robert J. Amdur, MD

Professor of Radiation Oncology and Residency Program Director
University of Florida College of Medicine

Dr. Amdur is the Medical Director for the UF department of Radiation Oncology and the Director of the UF Radiation Oncology Residency Training Program. Dr. Amdur has a special interest in treatment of patients with central nervous system, head and neck, and skin cancers. His research interests include outcome studies in radiation oncology and the practical application of research ethics. 

David Brizel, MD 

Leonard Prosnitz Professor of Radiation Oncology
Duke University Cancer Institute  

Dr. Brizel is a board certified radiation oncologist at Duke University Medical Center. Dr. Brizel specializes in Head and Neck cancer, non-melanoma skin cancer, targeted therapy, and tumor physiology. He led an in house randomized trial which was one of the first to demonstrate that concurrent chemoradiation was more efficacious than radiotherapy alone for locally advanced head and neck cancer. He served as the principal investigator of the pivotal randomized trial of amifostine in head and neck cancer. This study established proof of priniciple for the feasibility of pharmacologic radioprotection. He has served as co-Principal Investigator of a multinational randomized trial that tested the benefit of adding the hypoxic cell cytotoxin, tirapazamine, to concurrent chemoradiation in advanced head and neck cancer.Reduction of treatment induced morbidity has been a major interest of his.

‚ÄčDavid Raben, MD 

Professor of Radiation Oncology 
University of Colorado School of Medicine

Dr. David Raben trained at John Hopkins Hospital in radiation oncology,  is internationally recognized as an expert in the treatment of head and neck cancer, and is a professor at the University of Colorado Health. Over the past 20 years, Dr. Raben has focused on innovative radiation techniques to improve outcomes of head and neck cancer patients. In addition, he has interest and expertise in translational radiation oncology with a focus on delivery of precision drugs as well as exploration of molecular biomarkers and targets to enhance the effects of radiation therapy. From a national perspective, Dr. Raben remains an active participant in the NRG head and neck cancer steering committee and translational committee focusing on national, NCI approved clinical trials. In addition, Dr. Raben serves on the planning committees for the ASTRO HNC Symposiums and served as chair for the 2014 meeting. He has planned and implemented national meetings in targeted therapies and radiation in HNC over the past decade. Having developed the IMRT program in head and neck cancer at UCCC in 2002 he has continued to innovate with recent advances in submandibular and thyroid sparing approaches. Dr. Raben has successfully completed multiple Phase I trials using novel radio sensitizers in HNC. He currently is focused on studies related to combinations of DNA repair inhibitors or TGFb inhibitors with radiation.  

Avraham Eisbruch, MD

Professor of Radiation Oncology 
University of Michigan Health System 

Dr. Eisbruch joined the faculty of the University of Michigan in 1992 and is currently Associate Chair for clinical research in the Department of Radiation Oncology. His research interests include radiosensitization and highly conformal irradiation of head and neck cancer.